Anika Therapeutics, Inc. Depreciation
Anika Therapeutics, Inc. (ANIK) reported Depreciation of $1.50 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-07-29
- Anika Therapeutics, Inc. depreciation for the quarter ending 2026-06-30 was $1.50M, a 15.38% increase year-over-year.
- Anika Therapeutics, Inc. depreciation for the quarter ending 2026-03-31 was $1.40M, a 16.67% increase year-over-year.
- Anika Therapeutics, Inc. depreciation for the quarter ending 2025-12-31 was $1.40M, a 16.67% increase year-over-year.
- Anika Therapeutics, Inc. depreciation for the quarter ending 2025-09-30 was $1.40M, a 7.69% increase year-over-year.
- Anika Therapeutics, Inc. depreciation for fiscal 2025 was $5.40M, a 8.00% increase from fiscal 2024.
- Anika Therapeutics, Inc. depreciation for fiscal 2024 was $5.00M, a 2.04% increase from fiscal 2023.
- Anika Therapeutics, Inc. depreciation for fiscal 2023 was $4.90M, a 0.00% change from fiscal 2022.
- Anika Therapeutics, Inc. depreciation for fiscal 2022 was $4.90M, a 24.62% decline from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month | Depreciation 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $1.50M 10-Q · filed 2026-07-29 | $2.90M 10-Q · filed 2026-07-29 | $4.30M derived: sum of 3 quarters · filed 2026-07-29 | $5.70M derived: sum of 4 quarters · filed 2026-07-29 | |
| 2026-03-31 | $1.40M 10-Q · filed 2026-04-30 | $2.80M derived: sum of 2 quarters · filed 2026-04-30 | $4.20M derived: sum of 3 quarters · filed 2026-04-30 | $5.50M derived: sum of 4 quarters · filed 2026-07-29 | |
| 2025-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $2.80M derived: sum of 2 quarters · filed 2026-03-03 | $4.10M derived: sum of 3 quarters · filed 2026-07-29 | $5.40M 10-K · filed 2026-03-03 | |
| 2025-09-30 | $1.40M 10-Q · filed 2025-11-05 | $2.70M derived: sum of 2 quarters · filed 2026-07-29 | $4.00M 10-Q · filed 2025-11-05 | $5.10M derived: sum of 4 quarters · filed 2026-07-29 | |
| 2025-06-30 | $1.30M 10-Q · filed 2026-07-29 | $2.50M 10-Q · filed 2026-07-29 | $3.70M derived: sum of 3 quarters · filed 2026-07-29 | $5.00M derived: sum of 4 quarters · filed 2026-07-29 | |
| 2025-03-31 | $1.20M 10-Q · filed 2026-04-30 | $2.40M derived: sum of 2 quarters · filed 2026-04-30 | $3.70M derived: sum of 3 quarters · filed 2026-04-30 | $4.90M derived: sum of 4 quarters · filed 2026-04-30 | |
| 2024-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $2.50M derived: sum of 2 quarters · filed 2026-03-03 | $3.70M derived: sum of 3 quarters · filed 2026-03-03 | $5.00M 10-K · filed 2026-03-03 | |
| 2024-09-30 | $1.30M 10-Q · filed 2025-11-05 | $2.50M derived: sum of 2 quarters · filed 2025-11-05 | $3.80M 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | $1.20M 10-Q · filed 2025-07-30 | $2.50M 10-Q · filed 2025-07-30 | |||
| 2024-03-31 | $1.20M 10-Q · filed 2025-05-09 | ||||
| 2023-12-31 | $4.90M 10-K · filed 2026-03-03 | $6.40M 10-K · filed 2024-03-15 | |||
| 2022-12-31 | $4.90M 10-K · filed 2025-03-17 | $6.70M 10-K · filed 2023-03-16 | |||
| 2021-12-31 | $6.50M 10-K · filed 2024-03-15 | ||||
| 2020-12-31 | $6.10M 10-K · filed 2023-03-16 | ||||
| 2019-12-31 | $5.00M 10-K · filed 2022-03-11 | ||||
| 2018-12-31 | $4.90M 10-K/A · filed 2021-04-26 | ||||
| 2017-12-31 | $3.30M 10-K · filed 2020-03-06 | ||||
| 2016-12-31 | $2.70M 10-K · filed 2019-02-27 | ||||
| 2015-12-31 | $2.70M 10-K · filed 2018-02-27 | ||||
| 2014-12-31 | $2.60M 10-K · filed 2017-02-24 | $2.61M 10-K · filed 2015-03-13 | |||
| 2013-12-31 | $2.70M 10-K · filed 2016-03-10 | $2.68M 10-K · filed 2014-03-13 | |||
| 2012-12-31 | $2.50M 10-K · filed 2015-03-13 | ||||
| 2011-12-31 | $1.82M 10-K · filed 2014-03-13 | ||||
| 2010-12-31 | $1.31M 10-K · filed 2013-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |